BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Medical Coverage Guidelines are subject to change as new information becomes available. For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. O516.11.docx Page 1 of 7
Description: Boniva (ibandronate sodium) is a bisphosphonate that inhibits osteoclast-mediated bone resorption. It may be used in postmenopausal women for the treatment of osteoporosis. Definitions: T-Scores are reported as standard deviations (SD) World Health Organization (WHO) criteria: Normal: T-score within 1 SD Osteopenia: T-score of -1 to -2.5 SD Osteoporosis: T-score of -2.5 or worse SD Severe Osteoporosis: T-score of -2.5 or worse SD with fragility fractures High risk for fracture is defined as ONE of the following: Osteoporotic fracture Multiple risk factors for fracture (significantly low bone mass, frequent falls, limited movement, medical conditions likely to cause bone loss, medicines that may cause bone loss, e.g., seizure medicines, blood thinners, corticosteroids, high doses of vitamins A or D) Failed response (as defined by prescribing provider) to previous osteoporosis therapy Intolerant to previous osteoporosis therapy Fragility fracture: A fracture occurring spontaneously or after a minor trauma. Fracture Risk Assessment Tool (FRAX tool): The World Health Organization developed a risk assessment tool to assist providers in evaluating osteopenic individuals. The tool uses clinically proven risk factors to determine a 10 year probability of hip fracture and a 10 year probability for a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fractures). Treatment may be considered if the 10-year risk is 3% or more for hip fracture or if the risk for other bone fracture is 20% or more. The tool can obtained athttps://www.sheffield.ac.uk/frax/tool.aspx?country=9 Osteonecrosis of the jaw (ONJ): According to the American College of Rheumatology, ONJ can be diagnosed by the presence of exposed bone on oral examination, lasting more than eight weeks. ONJ risk factors include: invasive dental procedures (e.g. tooth extraction, dental implants, oral surgery), diagnosis of cancer, concomitant therapies (e.g. chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g. periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures). Bisphosphonates: Alendronate (e.g., Binosto, Fosamax), Etidronate (e.g., Didronel), Ibandronate (e.g., Boniva), Risedronate (e.g., Actonel), Zolendronate (e.g., Reclast, Zometa). Adult: Age 18 years and older O516.11.docx Page 2 of 7
Criteria: See Resources section for FDA-approved dosage. Initial Course of Treatment: Boniva for women is considered medically necessary with documentation of ALL of the following: 1. ONE of the following: T-score of -2.5 or worse (e.g., -3.0, -3.5), with or without osteoporotic fracture T-score of -1.0 or worse at the lumbar spine or femoral neck with a history of prior fragility fracture High risk for fracture as evidenced by multiple factors such as significantly low bone mass, frequent falls, limited movement, medical conditions likely to cause bone loss, medicines that may cause bone loss, (e.g., seizure medicines, blood thinners, corticosteroids, high doses of vitamins A or D) A low trauma fragility bone fracture A FRAX 10-year probability risk of 3% or more for a hip fracture OR 20% or more for other bone fracture, as assessed by the World Health Organization Fracture Risk Assessment Tool (FRAX tool) that can be obtained at: https://www.sheffield.ac.uk/frax/tool.aspx?country=9 2. Individual has failed, or is intolerant to, or has a contraindication to at least TWO of the following agents: Alendronate Etidronate Ibandronate Risedronate 3. Individual is receiving supplemental calcium and vitamin D with doses adjusted per usual laboratory monitoring 4. Creatinine clearance is equal to or greater than 30mL/min 5. Serum creatinine is obtained prior to each dose 6. There is evidence that a woman of child bearing potential is not pregnant or is unable to become pregnant 7. No evidence of hypocalcemia, has a serum calcium or corrected serum calcium within the normal range 8. Absence of hypersensitivity to the active substance or to any of the excipients or anaphylaxis to Boniva 9. Individual is not receiving another agent with the same active ingredient such as use with oral Boniva 10. Boniva is not being used concurrently with another bisphosphonate 11. A routine oral examination must be performed prior to treatment, individuals with risk factors for ONJ should receive appropriate preventive dentistry prior to initiation of Boniva O516.11.docx Page 3 of 7
Criteria: (cont.) Repeat Courses of Treatment: Repeat courses of Boniva injection is considered medically necessary with documentation of ALL of the following: 1. Achieved and maintains TWO of the following: Reduced incidence of new vertebral fractures in previously undeformed vertebrae Reduced incidence of non-vertebral fractures (e.g., ankle/foot, hip, humerus, pelvis, wrists, or other sites) Increased bone mineral density (e.g., lumbar spine, femoral neck, or total hip) 2. Individual is receiving supplemental calcium and vitamin D with doses adjusted per usual laboratory monitoring 3. Creatinine clearance is equal to or greater than 30 ml/min 4. Serum creatinine is obtained prior to each dose 5. There is evidence that a woman patient of child bearing potential is not pregnant or is unable to become pregnant 6. Individual is not receiving another agent with the same active ingredient such as use with oral Boniva 7. Boniva is not being used concurrently with another bisphosphonate 8. Individual has not developed any unacceptable drug toxicity (e.g., hypersensitivity, renal toxicity, osteonecrosis, atypical fractures, hypocalcemia, or severe bone/joint/muscle pains), contraindications or other exclusions to its continued use Boniva for all other indications not previously listed or if above criteria not met is considered experimental or investigational based upon: 1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 2. Insufficient evidence to support improvement of the net health outcome. These indications include, but are not limited to: Treatment with dosing or frequency outside the FDA-approved dosing and frequency O516.11.docx Page 4 of 7
Resources: Literature reviewed 07/05/18. We do not include marketing materials, poster boards and nonpublished literature in our review. 1. California Technology Assessment Forum. Vitamin D for the Prevention of Osteoporotic Fractures. Blue Shield of California Foundation. 2011. 2. Medline Plus. Ibandronate (Systemic). Developed 03/25/2004, revised 07/15/2015, accessed 09/01/2015. Boniva Package Insert. 12/07/2016: - FDA-approved indication and dosage: Indication For the treatment and prevention of postmenopausal osteoporosis. Optimal duration of use has not been determined. For individuals at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. Recommended Dose The recommended dose of Boniva injection is 3 mg every 3 months administered intravenously over a period of 15 to 30 seconds. Boniva injection must only be administered intravenously. Initial Approval Duration: 3 months Renewal Approval Duration: 12 months O516.11.docx Page 5 of 7
Non-Discrimination Statement: Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services. If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ s Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ s Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1 800 368 1019, 800 537 7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Multi-Language Interpreter Services: O516.11.docx Page 6 of 7
Multi-Language Interpreter Services: (cont.) O516.11.docx Page 7 of 7